CE Marking Versus FDA Clearance: Two Routes a Medical Device Takes to Market

A CE mark and an FDA clearance both tell you a medical device passed a regulatory bar before reaching the market, but they are not the same bar, and neither one is a stamp that says "proven best." In the European Union, CE marking signifies that a manufacturer has demonstrated conformity with the applicable regulation, usually the Medical Device Regulation (MDR) or the In Vitro Diagnostic Regulation (IVDR), often verified by an independent notified body. In the United States, "clearance" and "approval" are different words with different meanings: a 510(k) clearance rests on similarity to a device already on the market, a De Novo grant creates a new low-to-moderate-risk category, and a Premarket Approval (PMA) is a full safety-and-effectiveness review. A device sold on both continents has met two distinct sets of requirements, which is why the same product can carry both marks and still describe them separately.

What CE marking actually certifies

CE marking is a conformity declaration, not a government endorsement of a single product. Under the MDR, the manufacturer must show that the device meets the General Safety and Performance Requirements, maintain a quality management system, and assemble a clinical evaluation that ties the device's claims to evidence. For low-risk devices, the manufacturer can self-declare conformity. For higher-risk classes, an independent organization called a notified body reviews the technical documentation, the quality system, or both, and issues a certificate. The notified body is not a state regulator; it is an accredited private body designated to perform this assessment against the regulation's requirements.

Two features of the European model are easy to confuse. The MDR governs most devices, while the IVDR governs in vitro diagnostics, the tests that run on samples taken from the body rather than on the body itself. The IVDR substantially raised the share of diagnostics that need notified-body involvement, and it defined companion diagnostics, the tests that guide whether a specific therapy is appropriate, as a category with its own evidence and oversight expectations. A separate point is that CE marking comes paired with ongoing obligations: post-market surveillance and vigilance reporting mean the manufacturer must keep collecting real-world safety data and report serious incidents after the device is on the market.

What the three FDA routes signify

The United States sorts devices by risk into three classes and matches each to a route. The vocabulary matters, because "cleared" and "approved" are not synonyms.

510(k) clearance

Most moderate-risk devices reach the US market through a 510(k), a premarket notification. The core question is substantial equivalence: is this device as safe and effective as a legally marketed predicate device with the same intended use and comparable technological characteristics? A 510(k) frequently relies on bench testing, biocompatibility, and engineering data, with clinical data requested when nonclinical methods cannot answer a performance question. Clearance therefore certifies a comparison, not an independent proof that the device produces a health benefit from scratch. That is a reasonable design choice for well-understood device types, and it is also a limitation to understand: the bar is equivalence to something already trusted.

De Novo

When a device is low or moderate risk but genuinely novel, there may be no suitable predicate to compare against. The De Novo route lets the FDA classify such a device into Class I or II and create a new product code, along with any special controls that later devices of the same type must meet. It fills the gap between "similar enough for a 510(k)" and "high risk enough for a PMA."

Premarket Approval

For the highest-risk devices, typically Class III products that support or sustain life or carry significant potential for harm, the PMA is the most demanding route. Here the FDA conducts a scientific review of safety and effectiveness on the device's own evidence, usually including clinical data, design validation, and manufacturing inspection. This is the route the agency describes as "approval," and it is the closest US analogue to demonstrating a benefit directly rather than by comparison.

Why two markets means two bars

Building a device once does not collapse the two systems into one question. The EU route asks whether the device conforms to the regulation's safety and performance requirements, with a clinical evaluation and, for most classes, a notified body verifying the file. The US route asks, depending on class, whether the device is equivalent to a predicate, deserves a new low-to-moderate-risk classification, or clears an independent safety-and-effectiveness review. These questions overlap in spirit, both systems care about safety, both require evidence, both demand post-market monitoring, but they are not identical, and the labels are not transferable. A CE mark does not mean the FDA reviewed the device, and an FDA clearance does not mean a notified body certified it.

This is also why marketing language deserves a careful read. "FDA cleared" through a 510(k) is a real regulatory status, but it signifies substantial equivalence, not a full effectiveness trial. "CE marked" signifies conformity with the applicable EU regulation, which for a self-declared low-risk device involves no third party at all. Neither phrase, on its own, tells you the size of the clinical evidence base behind the device. The honest way to read either mark is as a floor the product had to clear, defined by its risk class and its route, rather than as a ranking of how well it works compared with alternatives.

For software as a medical device, the same logic applies with an extra wrinkle: both systems are still adapting to products that update frequently, learn from data, and blur the line between a tool and a diagnosis. Understanding which route a given product took, and what that route was designed to check, is the first step in reading its claims accurately.

This article is educational and is not legal or regulatory advice; anyone bringing a device to market should consult qualified regulatory professionals, and anyone making a health decision about a device should talk with their own clinician.